Valued at a market cap of $34.5 billion, Agilent Technologies, Inc. (A) is an original equipment manufacturer of a ...

Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications Agilent Technologies Inc. (NYSE: A) today ...

This was the stock's fourth consecutive day of losses.

Revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% on a core (1) basis compared with the first quarter of 2024. GAAP net income of ...

Agilent J&W VF-5ms is an inert 5% phenyl-methyl column for increased sensitivity, accuracy and instrument uptime. The column has the lowest guaranteed bleed specification of 1 pA at 325 °C (30 m ...

The company reported $1.68 billion in revenue at a 25.1% operating margin across its businesses in America, Europe, and Asia.

--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE ... When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion test, in the European Union: (a) resectable NSCLC patients with ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...